Skip to main content
Year archive

NEUREN PHARMACEUTICALS LIMITED — 2019 filings

All 33 regulatory filings released by NEUREN PHARMACEUTICALS LIMITED (NEU) in 2019, sourced directly from the official regulator.

33 Filings
2019 Period
2019 filings (33)
Filing Released Lang
2019 year-end update and 2020 outlook 2 pages 130.7KB
Capital/Financing Update
2019-12-11 English
Patent to 2034 granted in Europe for Neuren's NNZ-2591 2 pages 127.1KB
Regulatory Filings
2019-12-02 English
Phase 3 trial of trofinetide in Rett syndrome commences 4 pages 334.7KB
Regulatory Filings
2019-10-30 English
Neuren Corporate Presentation, October 2019 36 pages 1.1MB
Investor Presentation
2019-10-17 English
Appendix 4C - quarterly 5 pages 59.9KB
Interim / Quarterly Report
2019-10-16 English
Pause in Trading 1 page 112.2KB
Regulatory Filings
2019-10-15 English
FDA grants Orphan for both Phelan-McDermid and Pitt Hopkins 2 pages 125.9KB
Regulatory Filings
2019-10-15 English
FDA grants Orphan Drug Designation for NNZ-2591 in Angelman 2 pages 125.0KB
Regulatory Filings
2019-10-10 English
Neuren approaching key milestones in Q4 2019 2 pages 126.7KB
Capital/Financing Update
2019-09-19 English
Half Yearly Report and Accounts 15 pages 1.4MB
Interim / Quarterly Report
2019-08-27 English
Neuren advances pipeline for neurodevelopmental disorders 4 pages 173.3KB
Interim / Quarterly Report
2019-08-27 English
New patent granted for Neuren's NNZ-2591 in Japan 2 pages 125.4KB
Regulatory Filings
2019-08-15 English
Appendix 4C - quarterly 6 pages 143.9KB
Interim / Quarterly Report
2019-07-30 English
Neuren submits 3 NNZ-2591 Orphan Drug applications to FDA 2 pages 127.1KB
Regulatory Filings
2019-07-28 English
Neuren receives final payment from Lanstead Capital 1
Capital/Financing Update
2019-07-15 English
Chairman's Address at 2019 Annual Meeting of Shareholders 5 pages 149.0KB
AGM Information
2019-05-27 English
Results of Meeting 1 page 58.7KB
Declaration of Voting Results & Voting Rights Announcements
2019-05-27 English
NNZ-2591 positive effects in Angelman syndrome model 2 pages 126.2KB
Regulatory Filings
2019-05-16 English
NNZ-2591 positive effects in Pitt Hopkins syndrome model 2 pages 126.1KB
Capital/Financing Update
2019-05-16 English
Validation for NNZ-2591 neurodevelopmental disorder pipeline 2 pages 128.5KB
Capital/Financing Update
2019-05-16 English
Appendix 4C - quarterly 5 pages 60.4KB
Interim / Quarterly Report
2019-04-29 English
Notice of Annual General Meeting/Proxy Form 6 pages 214.1KB
AGM Information
2019-04-28 English
Update on development plan for NNZ-2591 2 pages 136.9KB
Capital/Financing Update
2019-04-25 English
Annual Report to shareholders 54 pages 1.4MB
Annual Report
2019-04-25 English
Appendix 4G 11 pages 127.0KB
Governance Information
2019-04-25 English
Neuren's Rett syndrome Phase 2 trial published in Neurology 4 pages 239.7KB
Regulatory Filings
2019-03-27 English
Preliminary Final Report and statutory accounts 33 pages 469.8KB
Annual Report
2019-02-26 English
Fundamentals strong as Neuren advances neuroscience pipeline 3 pages 132.1KB
Earnings Release
2019-02-26 English
NNZ-2591 positive effects in Phelan-McDermid syndrome model 2 pages 113.2KB
Regulatory Filings
2019-02-17 English
Plans for Phase 3 trial in Rett syndrome 2 pages 75.6KB
Regulatory Filings
2019-02-03 English
Neuren retains ex-North America, appoints investment bank 2 pages 109.1KB
Capital/Financing Update
2019-01-31 English
Appendix 4C - quarterly 5 pages 59.7KB
Interim / Quarterly Report
2019-01-30 English
Final Director's Interest Notice 2 pages 63.9KB
Director's Dealing
2019-01-02 English